再鼎医药-SB(09688.HK):全面包销发售美国预托股份 4月21日起复牌
格隆汇 4 月 21日丨再鼎医药-SB(09688.HK)发布公告,2021年4月20日(美国东部时间),公司向美国证交会提交8-K表格,宣布于美国发售477.6万股美国预托股份的定价为每股美国预托股份150.00美元,而500万股普通股的定价为每股普通股1,164.20港元。将予发行的美国预托股份数目占(i)截至2021年2月26日的60,078,450股发行在外美国预托股份约7.95%;及(ii)经发售扩大的美国预托股份约7.36%(假设可购买最多额外15%的美国预托股份的选择权尚未行使)。
公司估计是次发售所得款项净额将约为7.1543亿美元(或倘包销商悉数行使其购买额外美国预托股份的选择权,则为8.1805亿美元)。公司计划将是次发售所得款项净额主要用作增加业务及企业发展活动、推进多种候选药物的临床开发、拓展公司的商业化工作,及用于营运资金及其他一般企业用途。
其中,目前公司预期是次发售所得款项净额的用途如下:约30%的所得款项净额拨资新业务及企业发展以及授权机会;约30%的所得款项净额用作完成临床试验及推进新候选药物;约20%的所得款项净额用作拓展公司的商业化工作;约15%的所得款项净额用作提升公司的全球产品管线;及约5%的所得款项净额用作营运资金及其他一般企业用途。公司股份已自2021年4月20日上午九时正起于香港联交所暂停买卖,以待刊发本公告。公司已向香港联交所申请公司股份自2021年4月21日上午九时正(香港时间)起于香港联交所恢复买卖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.